Annis Gardner Whiting Capital Advisors, LLC Bei Gene, Ltd. Transaction History
Annis Gardner Whiting Capital Advisors, LLC
- $352 Billion
- Q2 2024
A detailed history of Annis Gardner Whiting Capital Advisors, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Annis Gardner Whiting Capital Advisors, LLC holds 36 shares of BGNE stock, worth $7,137. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36
Previous 36
-0.0%
Holding current value
$7,137
Previous $5.63 Million
8.77%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BGNE
# of Institutions
213Shares Held
45.5MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.1 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.39 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.03 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$989 Million0.52% of portfolio
-
Baillie Gifford & CO3.68MShares$730 Million0.42% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $20.6B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...